Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 15/20 | 0.63 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.63 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.63 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rilmakalim SCHEMBL221620 | 1.00 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9585284 | 1.00 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9293204 | 1.00 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9293211 | 1.00 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL5043882 | 0.99 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL1231447 | 0.99 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL4410403 | 0.99 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9295497 | 0.96 | ABCC9 (0.59) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9293330 | 0.92 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9294498 | 0.92 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| WO-2025078664-A1 | TREATMENT OF METASTATIC OR INVASIVE BRAIN CANCER | Celex Oncology Innovations Limited (GB) | 2025-04-17 | — | — | WO | claimed |
| US-20220347172-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2022-11-03 | — | — | US | claimed |
| EP-4048274-A1 | COMBINATION TREATMENTS FOR CANCER | Celex Oncology Innovations Limited (GB) | 2022-08-31 | — | — | EP | claimed |
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | disclosed |
| US-12508260-B2 | Combination treatments | Celex Oncology Innovations Limited (GB) | 2025-12-30 | — | — | US | disclosed |
| WO-2025078664-A1 | TREATMENT OF METASTATIC OR INVASIVE BRAIN CANCER | Celex Oncology Innovations Limited (GB) | 2025-04-17 | — | — | WO | disclosed |
| EP-4118430-B1 | MEASURING THE ELECTRIC ACTIVITY OF CELLS FOR THE EVALUATION OF METASTATIC POTENTIAL OF CANCER CELLS | CELEX ONCOLOGY INNOVATIONS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-20230139204-A1 | MEASURING ELECTRIC ACTIVITY OF CELLS FOR THE EVALUATION OF METASTATIC POTENTIAL OF CANCER CELLS | Celex Oncology Innovations Limited (GB) | 2023-05-04 | — | — | US | disclosed |
| EP-4118430-A1 | MEASURING THE ELECTRIC ACTIVITY OF CELLS FOR THE EVALUATION OF METASTATIC POTENTIAL OF CANCER CELLS | Celex Oncology Innovations Limited (GB) | 2023-01-18 | — | — | EP | disclosed |
| US-20220347172-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2022-11-03 | — | — | US | disclosed |
| EP-4048274-A1 | COMBINATION TREATMENTS FOR CANCER | Celex Oncology Innovations Limited (GB) | 2022-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508260-B2 | Combination treatments | SCN5A, SCN2B, SCNN1B | ABCC9 270/4885ABCC8 285/4885KCNJ11 109/4885 |
| US-20260076961-A1 | COMBINATION TREATMENTS | SCNN1B, SCN2B, SCNN1A | ABCC9 255/4885ABCC8 314/4885KCNJ11 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.